wuxi apptec
WuXi AppTec Expands To South Korea
China-based WuXi Apptec, an R&D capability and technology company, has opened an office in Seoul's Pangyo Techno Valley.
Huawei and WuXi AppTec Collaborate On Precision Medicine Cloud Platform
This strategic alliance will put a population genomics system on the cloud to support the delivery of China’s Precision Medicine Initiative.
WuXi AppTec To Build Biologics Solution Center
WuXi's Shanghai-based center, which will be operational by 2017, will provide integrated solutions for biologics discovery, development and clinical manufacturing.
AstraZeneca Expands Presence in Asia With Deals in China and Japan
AstraZeneca has entered a strategic alliance with WuXi AppTech and acquired Takeda's respiratory business.
WuXi & Lilly To Develop Cardiovascular Drug In China
As part of Lilly's ‘In China, For China’ strategy, the small molecule drug is intended to help the 276 million Chinese patients affected by high cholesterol.
WuXi NextCODE Selected To Run 100,000 Genomes Project
WuXi NextCODE has been appointed to carry out the first phase of an ambitious project to sequence 100,000 genomes in the UK.
WuXi’s Anti-Arthritis Antibody Accepted For CFDA Review
WuXi MedImmune Biopharmaceutical Co. Limited's anti-IL-6 monoclonal antibody is indicated for the treatment of rheumatoid arthritis.
WuXi To Build Third Cell Therapy Facility
The company's third cell therapy manufacturing facility will focus on chimeric antigen receptor T cells for cancer immunotherapy.
Enhanced Genomics Services For Chinese Researchers
WuXi's customers can look forward to enhanced sequence analysis capabilities thanks to a partnership with NextCODE Health.
